To view the PDF file, sign up for a MySharenet subscription.

MEDICLINIC INTERNATIONAL PLC - Directorate change - Dr Edwin Hertzog to retire as co deputy chairman and non-executive director of Remgro

Release Date: 22/11/2019 09:00
Code(s): MEI     PDF:  
Wrap Text
Directorate change - Dr Edwin Hertzog to retire as co deputy chairman and non-executive director of Remgro

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
LEI: 2138002S5BSBIZTD5I60
("Mediclinic", the "Company" or the "Group")

22 November 2019



The Company announces that Dr Edwin Hertzog will retire as co deputy Chairman and non-executive
director of Remgro Limited ("Remgro", Mediclinic’s principal shareholder), with effect from the close of
Remgro’s Annual General Meeting, scheduled to be held on 28 November 2019.

As previously announced by Mediclinic on 24 July 2019, Dr Hertzog will retire as Chairman of the Group
at the conclusion of the Company’s 2020 Annual General meeting. A search for Dr Hertzog's successor
as Chairman has been initiated and the Board will provide an update when appropriate.

About Mediclinic International plc

Mediclinic is an international private healthcare services group, established in South Africa in 1983, with
divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates.

The Group’s core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum
of care in such a way that the Group will be regarded as the most respected and trusted provider of
healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of
its markets.

Mediclinic comprises 77 hospitals, five sub-acute hospitals, 13 day case clinics and 22 outpatient clinics.
Hirslanden operates 17 hospitals, two day case clinics and three outpatient clinics in Switzerland with
more than 1 900 inpatient beds; Mediclinic Southern Africa operations include 53 hospitals (three of
which in Namibia), five sub-acute hospitals and nine day case clinics (four of which are operated by
Intercare) across South Africa, and more than 8 500 inpatient beds; and Mediclinic Middle East operates
seven hospitals, two day case clinics and 19 outpatient clinics with more than 900 inpatient beds in the
United Arab Emirates.

The Company’s primary listing is on the London Stock Exchange ("LSE") in the United Kingdom, with
secondary listings on the JSE Ltd in South Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group
based in the United Kingdom and listed on the LSE.

For further information, please contact:

Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)20 7954 9527

Investor queries
James Arnold, Head of Investor Relations, Mediclinic International plc
+44 (0)20 3786 8181

Media queries
FTI Consulting
Brett Pollard/Ciara Martin – United Kingdom
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE Ltd sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd

Date: 22/11/2019 09:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Email this JSE Sens Item to a Friend.

Share This Story